UK Markets closed

DAIICHI SANKYO CO. LTD (D4S.DU)

Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
28.30-0.26 (-0.91%)
As of 7:46PM CET. Market open.
Full screen
Previous close28.56
Open28.24
Bid0.00 x 0
Ask0.00 x 0
Day's range28.24 - 28.36
52-week range15.20 - 28.79
Volume50
Avg. volume2
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • 4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront
    Motley Fool

    4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront

    Here's why AstraZeneca agreed to pay Daiichi Sankyo another enormous sum to develop and commercialize an experimental cancer drug.

  • AstraZeneca bets up to $6 billion on new Daiichi cancer drug
    Reuters

    AstraZeneca bets up to $6 billion on new Daiichi cancer drug

    The British drugmaker has been bolstering its portfolio of cancer therapies, particularly ADCs, a major area of focus for the company as it also ploughs on with its coronavirus vaccine candidate. AstraZeneca said on Monday it would make staggered upfront payments totalling $1 billion to Daiichi for an experimental drug called DS-1062, which belongs to a promising class of therapies called antibody drug conjugates (ADC). The deal will not affect 2020 earnings forecast, AstraZeneca said.

  • Daiichi Sankyo in talks with AstraZeneca on virus vaccine supply in Japan
    Reuters

    Daiichi Sankyo in talks with AstraZeneca on virus vaccine supply in Japan

    Daiichi Sankyo Co is in discussions to provide supplies of a potential coronavirus vaccine now being developed by AstraZeneca Plc and the University of Oxford for use in Japan. The discussion follows a flurry of supply deals signed by the British drug maker for its experimental COVID-19 vaccine as it ramps up efforts for wider trials of the potential treatment. Daiichi Sankyo said in a statement on Friday that one of its subsidiaries would receive undiluted solution of the vaccine and then carry out formulation procedures, packaging, and storage in Japan.